Renaissance Technologies LLC Sells 302,600 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Renaissance Technologies LLC reduced its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 11.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,347,477 shares of the biopharmaceutical company’s stock after selling 302,600 shares during the period. Renaissance Technologies LLC’s holdings in Catalyst Pharmaceuticals were worth $58,124,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Keebeck Wealth Management increased its position in Catalyst Pharmaceuticals by 9.3% during the 1st quarter. Keebeck Wealth Management now owns 25,176 shares of the biopharmaceutical company’s stock worth $623,000 after buying an additional 2,149 shares during the period. Inceptionr LLC acquired a new position in shares of Catalyst Pharmaceuticals in the first quarter valued at about $212,000. Systematic Financial Management LP grew its stake in shares of Catalyst Pharmaceuticals by 3.4% in the first quarter. Systematic Financial Management LP now owns 747,515 shares of the biopharmaceutical company’s stock valued at $18,509,000 after acquiring an additional 24,273 shares in the last quarter. Walleye Capital LLC increased its position in Catalyst Pharmaceuticals by 253.3% during the first quarter. Walleye Capital LLC now owns 71,149 shares of the biopharmaceutical company’s stock worth $1,762,000 after acquiring an additional 51,010 shares during the period. Finally, Globeflex Capital L P raised its stake in Catalyst Pharmaceuticals by 54.2% in the 1st quarter. Globeflex Capital L P now owns 450,580 shares of the biopharmaceutical company’s stock worth $11,156,000 after purchasing an additional 158,372 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the stock. Robert W. Baird downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 7th. HC Wainwright cut shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Oppenheimer cut Catalyst Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 7th. Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a research report on Thursday, May 7th. Finally, Weiss Ratings upgraded Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, Catalyst Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Catalyst Pharmaceuticals Stock Performance

Catalyst Pharmaceuticals stock opened at $31.49 on Monday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56. The stock has a market capitalization of $3.86 billion, a P/E ratio of 18.10, a price-to-earnings-growth ratio of 0.96 and a beta of 0.74. The stock has a fifty day moving average of $31.39 and a 200-day moving average of $27.33.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).